Cost of chemotherapy‐induced thrombocytopenia among patients with lymphoma or solid tumors

BACKGROUND The purpose of this study was to estimate the mean incremental cost of chemotherapy‐induced thrombocytopenia and the drivers of cost. Another goal was to estimate the impact of depth and duration of thrombocytopenia on the cost of thrombocytopenia. METHODS A retrospective cohort, consisting of a random sample of 75 solid tumor or lymphoma patients who developed chemotherapy‐induced thrombocytopenia (≤ 50,000 platelets per μl), was chosen. The number of each type of resource used during 217 cycles with and 300 cycles without thrombocytopenia were multiplied by the cost of each resource and summed to yield the total cost of care (in 1999 dollars from the provider's perspective). RESULTS Compared with cycles without thrombocytopenia, the mean incremental cost of thrombocytopenia was $1037 per cycle. However, 60% of cycles were usual cost, with a mean cost of thrombocytopenia of $43 per cycle less than control cycles. Twelve percent of cycles were high cost (mean incremental cost = $612 per cycle); 28% were very high cost (mean incremental cost = $3519). The excess cost during high‐cost cycles was due to high consumption of prophylactic platelet transfusions and during very high‐cost cycles to both higher platelet transfusion consumption and to a high incidence of major bleeding episodes. CONCLUSIONS Although thrombocytopenia is a common complication of chemotherapy, only 40% of cycles with thrombocytopenia would be considered high or very high cost. Interventions targeted at this subset of cycles could significantly reduce the cost of thrombocytopenia provided they are initiated early enough in the chemotherapy experience to be effective. Cancer 2003;97:1541–50. © 2003 American Cancer Society. DOI 10.1002/cncr.11195 Thrombocytopenia is a common complication of chemotherapy among patients with solid tumors, but it contributes significantly to the total cost of care in only 40% of cycles in this population. Targeting interventions at high‐cost cycles may have significant financial impact.